Its announcement comes around the heels of an identical licensing arrangement available in February to Adastra Labs, which had until finally now centered on crafting cannabis extracts. Adastra's license also enables it to create and market psilocybin and psilocin – hallucinogens far more commonly generally known as magic mushrooms that develop ef